• Explore /
  • Poster
  • / Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).

Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).

Abstract Poster

Authors

null

Connor Wells

Barts Cancer Institute, London, United Kingdom

Connor Wells , Evan Ferrier , Audreylie Lemelin , Thomas Powles , Sumanta Kumar Pal , Hedyeh Ebrahimi , Neeraj Agarwal , Benoit Beuselinck , Georg A. Bjarnason , Lori Wood , Christina M. Canil , Renee Maria Saliby , Guillermo de Velasco , Rana R. McKay , Ben Tran , Cristina Suárez , Arnoud J. Templeton , Toni K. Choueiri , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 395)

DOI

10.1200/JCO.2024.42.4_suppl.395

Abstract #

395

Poster Bd #

F19

Abstract Disclosures

Similar Posters

First Author: Audreylie Lemelin

First Author: Neil J. Shah

First Author: Daniel M. Geynisman

First Author: Ana-Alicia Beltran-Bless